Inflammatory and metabolic markers and comorbidities remission following sleeve gastrectomy: A single center one-year cohort study |
| |
| Institution: | 1. Department of Internal Medicine, Endocrinology, Shahid Beheshti University of Medical Sciences, Tehran, Iran;2. Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran;3. Department of Internal Medicine, Loghman Hakim Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran;4. Internal medicine assistant, school of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran;5. School of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran;1. Department of Neurology, Hospital São Paulo, Federal University of São Paulo, São Paulo, Brazil;2. Neurology Program and Stroke Center, Hospital Israelita Albert Einstein, São Paulo, Brazil;1. Department of General Practice, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands;2. Leidsche Rijn Julius Healthcare Centers, Utrecht, the Netherlands;1. Health Sciences Ph.D. Program, Health Sciences Institute, University of Veracruz, Mexico;2. Health Sciences Institute, University of Veracruz, Mexico;3. Public Health Institute, University of Veracruz, Mexico;4. Faculty of Medicine, University of Veracruz, Mexico;5. Family Medicine Unit No. 66, Mexican Institute of Social Security, Mexico;6. Division of Metabolism, UMAE 14, Mexican Institute of Social Security, Mexico;7. Clinical Analysis Laboratory of the University Clinic for Reproductive and Sexual Health, University of Veracruz, Mexico;1. Faculdade de Medicina de Marília, Marília, Brazil;2. Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil;3. Departamento de Fisiologia, Universidade Federal de São Paulo, São Paulo, Brazil;1. Department of Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands;2. Hadoks, The Hague, the Netherlands;3. Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain;4. Centro de Salud Casco Antiguo Cartagena, Murcia, Spain;5. Spanish Diabetes Association, Catholic University of Murcia, Servicio Murciano de Salud, Cartagena, Murcia, Spain;6. Diabetes Research Centre, University of Leicester, Leicester, UK;7. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands;1. Department of Public Health and Primary Care / Health Campus The Hague, Leiden University Medical Centre, The Hague, the Netherlands;2. National Institute for Public Health and the Environment, Bilthoven, the Netherlands |
| |
| Abstract: | Background and aimObesity is a global concern with several health-related complications. Bariatric surgeries are major treatment options in patients with obesity and other comorbidities. This study aims to investigate the effects of sleeve gastrectomy on metabolic indexes, hyperechogenic liver changes, inflammatory state, diabetes, and other obesity-related comorbidities remission after the sleeve gastrectomy.MethodsThis prospective study was conducted on patients with obesity candidates for laparoscopic sleeve gastrectomy. Patients were followed for one year after the surgery. Comorbidities, metabolic and inflammatory parameters were assessed before and one- year after the surgery.Results137 patients (16 males, 44 in the DM group) underwent sleeve gastrectomy. One year after the study, obesity-related comorbidities improved significantly; diabetes had complete remission in 22.7% and partial remission in 63.6% of patients. Hyper-cholesterolemia, hyper-triglyceridemia, and hyper-uricemia also improved in 45.6%, 91.2%, and 69% of the patients. Metabolic syndrome indexes improved in 17.5% of the patients. Also, the prevalence of hyperechogenic changes in the liver has declined from 21% before the surgery to 1.5% after that. Based on logistic regression analysis, increased levels of HbA1C reduced the chance of diabetes remission by 0.9%. In comparison, every unit of increased BMI before the surgery improved the case of diabetes remission by 16%.ConclusionLaparoscopic sleeve gastrectomy is a safe and effective treatment option in patients with obesity and diabetes. Laparoscopic sleeve gastrectomy alleviates BMI and insulin resistance and effectively improves other obesity-related comorbidities such as Hypercholesterolemia, hyper-triglyceridemia, hyper-uricemia, and hyperechogenic changes of the liver. HbA1C and BMI before the surgery are notable predictors of diabetes remission within the first year after the surgery. |
| |
| Keywords: | Bariatric surgery Type 2 diabetes Comorbidity Diabetes remission Inflammation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
